Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bullous lesions in scleroderma.

Adrienne Rencic1, Supriya Goyal, Mona Mofid

  • 1Department of Dermatology, of Johns Hopkins University, School of Medicine, Baltimore, MD, USA.

International Journal of Dermatology
|July 9, 2002
PubMed
Summary

Bullous lesions in scleroderma are rare, occurring in 7.5% of cases. These eruptions can stem from inflammatory, fibrotic, autoimmune mechanisms, or even as a complication of therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dupilumab-induced ocular surface disease: a primer.

Drug and therapeutics bulletin·2023
Same author

Dupilumab-induced ocular surface disease: a primer.

BMJ case reports·2022
Same author

Erythroid-specific transcriptional changes in PBMCs from pulmonary hypertension patients.

PloS one·2012
Same author

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Arthritis and rheumatism·2008
Same author

Lymph node biopsy results for desmoplastic malignant melanoma.

Cutis·2007
Same author

Comparison of 1-site versus 2-site phacotrabeculectomy.

Journal of cataract and refractive surgery·2006

Area of Science:

  • Dermatology
  • Rheumatology
  • Immunopathology

Background:

  • Bullous lesions are an uncommon manifestation in localized or systemic scleroderma.
  • Reported histologic patterns include lichen sclerosus et atrophicus-like, lymphangiectatic blisters, and autoimmune blistering diseases.

Observation:

  • This study investigated the frequency, clinical, and immunopathologic features of patients with scleroderma and bullous eruptions.
  • A retrospective analysis of 53 scleroderma cases over 8 years identified four patients with bullous lesions.

Findings:

  • The four cases presented diverse bulla formation mechanisms: lymphangioma-like, bullous lichen sclerosus et atrophicus-like, epidermolysis bullosa acquisita, and penicillamine-induced pemphigus foliaceus.
  • One case demonstrated bullae as a complication of therapy for systemic scleroderma.

Related Experiment Videos

Implications:

  • Bullous scleroderma can arise from various pathogenetic pathways, including inflammatory, fibrotic/obstructive, and autoimmune processes.
  • Understanding these mechanisms is crucial for accurate diagnosis and management of bullous eruptions in scleroderma patients.